Clinical Trial Search

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.32; -0.38; -0.47 Units on a Scale

Primary: Change in the PANSS Total Score From Baseline to the Last Postrandomization Assessment in the Double-blind Period of the Study. — -9.8; -17.3; -13.8; -7.9 units on a…

Primary: Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic Asthma — -11.96; -5.31; 0.72; 5.08 Percentage of Change

Primary: Major Vascular Events (MVE) — 1553; 1477; 1537; 1493 Participants

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period — -0.23; -0.33; -0.45 Scores on a scale

Primary: Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment — 8; 2 Participants

Primary: Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given…

Primary: Change From Baseline in A1C at Week 24 — -0.61; -0.76; 0.18 Percent — p=<0.001

Primary: Number of Patients With Clinical Adverse Experiences (CAEs) — 125; 32 Participants

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over 2 Weeks — -0.24; -0.37; -0.47 Units on a Scale

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale

Primary: The Grip Strength — 98.3; 62.6 Percentage of opposite side — p=<0.05

Primary: Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months — 86.0; 14.0 percentage of participants

Primary: Number of Participants Not Requiring Renal Replacement Therapy (RRT) — 3; 1 participants

Primary: Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2…